Thread by @subatomicdoc

Another study of interest on systemic radiation in metastatic prostate cancer

meetinglibrary.asco.org/record/187000/…

TheraP: randomised phase II trial of 177Lu-PSMA-617 vs cabazitaxel in progressive metastatic castration resistant prostate cancer (mCRPC) #ASCO20 #pcsm #radonc
H1/

ANZUP 1603 with @Prof_IanD et al evaluated radionuclide Lutetium-177 linked to prostate specific membrane antigen (177-Lu-PSMA-617) 6-8Gbq every six weeks x 6 vs. cabazitaxel 20 mg/m2 q 3 wks x 10 in men with mCRPC progressing after paclitaxel #ASCO20 #pcsm
H2/

200 men randomized to each drug stratified by prior abirateron/enzalutamide use, >20 metastases, study site. Median age 72 years old

Primary endpoint response rate, secondary PSA relapse free survival and overall survival.
#ASCO20 #pcsm #radonc
H3/

Median f/u 11.3 months.

177LuPSMA Cabazitaxel
ORR 66% 37%. p<0.001
Gr3-4 toxicity 32% 49%. p NR

For PSA RFS, LuP better than Cab, HR 0.63, 95%CI 0.45-0.88, P=0.007

OS not reported.
#ASCO20 #pcsm
H4/

It's premature data but #radonc should pay attention. We should stop thinking about linac-based therapy and think about radiation as medicine. If we can treat within mm, why not within microns?
@rweichselbaum @sophia_kamran
#ASCO20 #pcsm
H5/

I give Ra-223 in my practice. If #radonc wants to keep up with the molecular medicine revolution, it's worth being involved in the research and practice of molecular oncology including in polymetastatic disease.
#ASCO20 #pcsm
H6/